{"id":11265,"date":"2026-05-26T21:34:00","date_gmt":"2026-05-26T19:34:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=86cb45a88b278eb4b49c511e5d33ed28"},"modified":"2026-05-26T21:34:00","modified_gmt":"2026-05-26T19:34:00","slug":"zs-named-a-leader-in-idc-marketscape-for-life-sciences-rd-strategic-consulting","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11265","title":{"rendered":"ZS named a Leader in IDC MarketScape for Life Sciences R&D Strategic Consulting"},"content":{"rendered":"

EVANSTON, Ill.--(BUSINESS WIRE)--ZS, a global management consulting and technology firm, has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D Strategic Consulting Services 2026 Vendor Assessment<\/a> (IDC #US53009826, May 2026).<\/p><\/a><\/a>

\nThe IDC MarketScape evaluates life sciences R&D strategic consulting providers based on their capabilities and strategies, assessing how well vendors support areas such as R&D operating model design, data and digital health strategy, AI-enabled transformation and end-to-end execution.<\/p>

\n\u201cLife sciences organizations are navigating increasingly complex R&D transformation challenges, as scientific innovation, data and AI reshape decision-making,\u201d said Rohan Fernando, ZS\u2019s managing principal for its life sciences R&D and medical practice area. \u201cWe believe this recognition in the IDC MarketScape reflects ZS\u2019s ability to connect strategy, AI, data and technology across the full life cycle, helping clients transform ideas into impact and improve outcomes for all.\u201d<\/p>

\nThe MarketScape highlights several core strengths of ZS\u2019s strategic consulting capabilities, including:<\/p>

    \n
  1. \nIn silico drug development to drive ROI:<\/b> \u201cZS is investing in in silico clinical development to help pharma scale ROI and is planning on deepening engagement with R&D domain leaders but also with enterprise IT and technology organizations to drive cross-functional transformation, and on embedding \"patient-centricity\" in its strategic frameworks, trial design methodologies, and evidence strategies.\u201d<\/li>\n
  2. \nEnd-to-end perspectives and solutions:<\/b> \u201cZS brings to the table integrated thinking and solutions spanning strategy and transformation, insights and analytics, technology, platform services, and accelerators across the life sciences value chain.\u201d<\/li>\n
  3. \nDeep domain expertise: <\/b>\u201cZS has over 250 people with advanced scientific degrees, and ZS employees have expertise in over 120 disease areas. 20% of its R&D leadership has over 15 years of R&D industry leadership experience.\u201d<\/b><\/li>\n
  4. \nAsset-based differentiation: <\/b>\u201cZS partners with over 200 pharma [companies] on R&D programs and has developed over 30 R&D technology products and accelerators, including ZAIDYN (its clinical platform for feasibility and enrollment)\u201d<\/li>\n
  5. \nAgentic AI in strategic consulting: <\/b>The three key agentic AI use cases where ZS supports the life sciences industry with its strategic consulting offerings are content authoring, in silico and digital twin\u2013driven trial design, and the use of agentic AI in clinical data management \u2014 for quality control, data standardization, transformation, and the generation of submission ready outputs.<\/li>\n
  6. \nGenAI decision systems in strategic consulting: <\/b>The three key GenAI use cases where ZS supports the life sciences industry with its strategic consulting offerings are AI-driven clinical workflow transformation, trial design optimization, and risk based quality management.\u201d<\/li>\n<\/ol>

    \nAs the life sciences industry increasingly shifts from AI experimentation to enterprise-scale value realization, organizations are seeking partners that can bridge strategy and execution, integrate domain expertise with data and digital capabilities, and support sustained transformation. ZS continues to focus on helping clients navigate this shift and advance R&D performance.<\/p>

    \nFor more information, visit https:\/\/www.zs.com<\/a>.<\/p>

    \nAbout ZS<\/b><\/p>

    \nZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 15,000 employees in over 40 offices worldwide. To learn more, visit www.zs.com<\/a> or follow us on LinkedIn<\/a>.<\/p>

    \nAbout IDC MarketScape<\/b><\/p>

    \nAbout IDC MarketScape: IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier\u2019s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.<\/p> Contacts<\/b>

    \nMedia contact\n<\/b>Maryam Ayromlou\nRuder Finn\nZS-RFMedia@ruderfinn.com<\/a>+1 703 474 5685<\/p>","protected":false},"excerpt":{"rendered":"

    EVANSTON, Ill.–(BUSINESS WIRE)–ZS, a global management consulting and technology firm, has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D Strategic Consulting Services 2026 Vendor Assessment (IDC #US53009826, May 2026).
    \nT…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11265","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11265"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11265\/revisions"}],"predecessor-version":[{"id":11266,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11265\/revisions\/11266"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}